153Sm-EDTMP for bone pain palliation in metastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue SUPPL. 1, 2004, Pages

  Maini, Carlo L ^a,b   Bergomi, Serenella ^a   Romano, Luisa ^a   Sciuto, Rosa ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

153Sm; Bone metastases; Bone pain; Breast cancer; Radionuclide therapy

Indexed keywords

LEXIDRONAM SAMARIUM SM 153; MEDRONATE TECHNETIUM TC 99M; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

BLADDER; BLOOD TOXICITY; BONE DISEASE; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CARCINOMA; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SAFETY; ELECTRON TRANSPORT; HALF LIFE TIME; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR STABILITY; RADIOISOTOPE THERAPY; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TISSUE DISTRIBUTION; BONE TUMOR; BREAST TUMOR; FEMALE; MAXIMUM TOLERATED DOSE; METASTASIS; METHODOLOGY; PAIN; PALLIATIVE THERAPY; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RADIATION INJURIES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 3042584353     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1540-y     Document Type: Review

References (45)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61-66.
2. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991; 18:11-15.
3. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003; 97 (Suppl):834-839.
4. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000; 88 (Suppl):3033-3037.
5. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 2003; 29:321-327.
6. Hoskin PJ. Radiotherapy for bone pain. Pain 1995; 63:137-139.
7. Dearnaley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM, Lewington VJ. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol 1992; 4:101-107.
8. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994; 30:1187-1194.
9. McEwan AJ. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997; 27:165-182.
10. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42:895-906.
11. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88 (Suppl):2934-2939.
12. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Q J Nucl Med 2001; 45:91-99.
13. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28:495-504.
14. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989; 7:1926-1931.
15. Podoloff DA, Kasi LP, Kim EE, Fossella FV, Bhadkamar VA. Evaluation of Sm-153-EDTMP as a bone imaging agent during a therapeutical trial. J Nucl Med 1991; 32:A918.
16. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, Gordon EE. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34:1031-1036.
17. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose of samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991; 27:1084-1086.
18. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30:1814-1818.
19. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63-69.
20. Heggie JC. Radiation absorbed dose calculations for samarium-153-EDTMP localized in bone. J Nucl Med 1991; 32:840-844.
21. Logan KW, Volkert WA, Holmes RA. Radiation dose calculations in persons receiving injection of samarium-153-EDTMP. J Nucl Med 1987; 28:505-509.
22. 153Sm-EDTMP in patients with painful bone metastases of breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:716-718.
23. Farhanghi M, Homes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33:1451-1458.
24. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34:1839-1844.
25. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15:784-795.
26. Alberts AS, Smit BJ, Louw WKA, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997; 43:175-179.
27. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jacobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, Larikka M, Nikula T, Romppainen ML, Vanaselja T, Vuorimaki O. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38 (Suppl I):123-127.
28. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol 1993; 20 (Suppl 2):22-26.
29. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D. A dose-controlled study of 153-Sm-ethylenediaminete-tramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33:1583-1591.
30. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574-1581.
31. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26:2-7.
32. Donaldson G. A new approach to calculating pain measurements for cancer patients. Sci Comput Automation 1992; January:45-48.
33. Li L, Liang Z, Deng H, Kuang A, Tan T, Luo S. Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J 2002; 115:1096-1098.
34. Dolezal J, Vizd'a J, Cermakova E. Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP. Vnitr Lek 2003; 49:189-193.
35. Maini CL, Sciuto R, Romano L, Bergomi S. Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. J Exp Clin Cancer Res 2003; 22:71-74.
36. 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41:647-654.
37. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66:101-109.
38. Samaratunga RC, Thomas SR, Hinnefeld JD, von Kuster LC, Hyams DM, Moulton JS, Matthew I, Sperling MI, Maxon HR III. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from Rhenium-186(Sn)-HEDP. J Nucl Med 1995; 36:336-350.
39. Mauch PM. Treatment of metastatic cancer to bone. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. Philadelphia: Lippincott; 1993:1564-1579.
40. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG, Broccatelli M. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 1996; 17:799-804.
41. Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, Ferraironi A, Rea S, Maini CL. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ter 1998; 149:43-47.
42. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79-86.
43. Turner JH, Claringold PG, Martindale AA. Samarium-153-EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastases. Eur J Nucl Med 1992; 16:s125.
44. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med 2002; 29:1271-1275.
45. Wallenstein SL. Measurement of pain and analgesia in cancer patients. Cancer 1984; 53:2260-2266.